Experience

Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies, Inc. Aimmune Therapeutics sold 11,499,999 shares of its…

Davis Polk advised the joint book-running managers in connection with the $207 million SEC-registered follow-on offering of common stock of Atara Biotherapeutics, Inc. The common stock…

Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of 10,000,000 shares of common stock of Natera, Inc. Natera’s common…

Davis Polk advised Capio AB (publ) on its initial public offering and listing of shares on NASDAQ Stockholm. Assuming full exercise of the overallotment option, 52,934,872 shares were sold…

Davis Polk advised the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $1 billion aggregate principal amount of its 5.250% senior notes due 2022…

Davis Polk advised the sole structuring advisor and sole bookrunner in a Rule 144A offering by Impax Laboratories, Inc. of its 2.00% convertible senior notes due 2022. In addition,…

Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common shares of Cynapsus Therapeutics Inc., including 675,000 common…

Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American Depositary Shares (“ADSs”) representing 304,483,760 ordinary…

Davis Polk advised the underwriters as joint global coordinators on the initial public offering and listing on the Main Board of the Stock Exchange of Hong Kong Limited of 3SBio Inc. …

Davis Polk advised Auris Medical Holding AG (“Auris Medical”) on its $25.1 million public offering of 5,275,000 of its common shares. The common shares are listed on the NASDAQ Global…